急性髓系白血病的靶向治疗进展

急性髓系白血病是一组高度异质性的克隆性疾病,既往以细胞毒药物为主的化疗方案是治疗的基本骨架,但已难以满足临床治疗需求。近年来,深度测序技术的发展和靶向药物的应用开启了急性髓系白血病靶向治疗的大门,也为急性髓系白血病的治疗带来了巨大的进步。随着研究的深入,靶向药物耐药、联合治疗毒性叠加、缺乏有效靶点等问题也逐渐凸显出来,为治疗策略选择提出了新的挑战。未来,深入探讨急性髓系白血病发病机制,开发和合理使用靶向药物和免疫治疗,将有望进一步提高急性髓系白血病疗效,推动其进入个体化精准治疗的新时代。

Advances in targeted therapy for acute myeloid leukemia

Acute myeloid leukemia(AML)is a highly heterogeneous clonal disease. Although traditional cytotoxic chemotherapy is still the fundamental treatment, it fails to meet the clinical requirements. In recent years, advances in deep sequencing and applications of targeted drugs have opened a new era of targeted therapy for AML. However, issues such as drug resistance, overlaid toxicity of combined therapy, and lack of effective targets have gradually emerged and presented new challenges. We believe that in the near future, digging into the pathogenesis of AML, developing and appropriately using targeted drugs and immunotherapy will continue improving the efficacy of AML and promoting the individualized precision therapy.